Park Place Capital Corp Has $515,000 Holdings in Pfizer Inc. (NYSE:PFE)

Park Place Capital Corp increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.2% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 18,570 shares of the biopharmaceutical company’s stock after acquiring an additional 756 shares during the period. Park Place Capital Corp’s holdings in Pfizer were worth $515,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new stake in Pfizer in the 4th quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC grew its holdings in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer in the 4th quarter valued at approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on PFE. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, June 26th. Morgan Stanley raised their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $35.54.

Pfizer Price Performance

Pfizer stock opened at $28.22 on Tuesday. The business has a 50 day simple moving average of $27.90 and a 200 day simple moving average of $27.69. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80. The company has a market capitalization of $159.91 billion, a PE ratio of -470.25, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same period last year, the firm posted $1.23 EPS. The business’s revenue was down 19.5% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a yield of 5.95%. Pfizer’s dividend payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.